AIMS: To assess the levels of soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) in patients with familial Mediterranean fever (FMF). METHODS: Plasma levels of sVEGFR-1 were investigated in 33 FMF patients in an attack-free period (mean age 30.8 years; males/females 10/23), in 15 patients with acute FMF attack (mean age 32.7 years; males/females 7/8), and 19 healthy controls (mean age 32 years; males/females 11/8). Levels of sVEGFR-1 were also compared among patients who were receiving colchicine and those who were not. RESULTS: Plasma sVEGFR-1 levels were 3.49+/-1.10, 3.53+/-1.02, and 0.37+/-0.28 ng/ml for FMF patients in the attack-free period, FMF patients with acute attack, and healthy controls, respectively. Plasma sVEGFR-1 levels were significantly higher in FMF patients with and without acute attack compared to the control group (p<0.05). sVEGFR-1 levels were not statistically significant between patients with acute attack and attack-free FMF patients (p>0.05). The plasma levels of sVEGFR-1 were also comparable in colchicine treated and untreated patients. CONCLUSION: Our data suggest that sVEGFR-1 may have a role in the ongoing inflammatory cascade in FMF.
AIMS: To assess the levels of soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) in patients with familial Mediterranean fever (FMF). METHODS: Plasma levels of sVEGFR-1 were investigated in 33 FMFpatients in an attack-free period (mean age 30.8 years; males/females 10/23), in 15 patients with acute FMF attack (mean age 32.7 years; males/females 7/8), and 19 healthy controls (mean age 32 years; males/females 11/8). Levels of sVEGFR-1 were also compared among patients who were receiving colchicine and those who were not. RESULTS: Plasma sVEGFR-1 levels were 3.49+/-1.10, 3.53+/-1.02, and 0.37+/-0.28 ng/ml for FMFpatients in the attack-free period, FMFpatients with acute attack, and healthy controls, respectively. Plasma sVEGFR-1 levels were significantly higher in FMFpatients with and without acute attack compared to the control group (p<0.05). sVEGFR-1 levels were not statistically significant between patients with acute attack and attack-free FMFpatients (p>0.05). The plasma levels of sVEGFR-1 were also comparable in colchicine treated and untreated patients. CONCLUSION: Our data suggest that sVEGFR-1 may have a role in the ongoing inflammatory cascade in FMF.
Authors: Muhammet Murat Celik; Eyup Buyukkaya; Nilgul Ustun; Alper Bugra Nacar; Mustafa Kurt; Mehmet Fatih Karakas; Perihan Bilen; Mehmet Duru; Nihat Sen; Adnan Burak Akcay Journal: Wien Klin Wochenschr Date: 2015-03-19 Impact factor: 1.704
Authors: Yusuf Tavil; Kemal Ureten; Mehmet Akif Oztürk; Nihat Sen; Mehmet Güngör Kaya; Mustafa Cemri; Atiye Cengel Journal: Clin Rheumatol Date: 2007-07-24 Impact factor: 2.980